Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance

Mayo Clinic Proceedings

Volumn 79, Issue 8, 2004, Pages 1048-1054

  Miller, Loren G ^a   Tang, Angela W ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b ST MARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFALOTIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MECILLINAM; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMBINATION CHEMOTHERAPY; CYSTITIS; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG USE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SIDE EFFECT; URINARY TRACT INFECTION;

EID: 3442892932     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.8.1048     Document Type: Review

References (45)

1. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000; 10:509-515.
2. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745-758.
3. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328-1334.
4. Bent S, Nallamothu BK, Simel DL, Finn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287:2701-2710.
5. Wallach J. Interpretation of Diagnostic Tests. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
6. Walter FG, Gibly RL, Knopp RK, Roe DJ. Squamous cells as predictors of bacterial contamination in urine samples. Ann Emerg Med. 1998;31:455-458.
7. Ronald AR, Harding GK. Complicated urinary tract infections. Infect Dis Clin North Am. 1997;11:583-592.
8. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother. 2000;46(suppl 1):1-7.
9. Fihn SD. Acute uncomplicated urinary tract infection in women. N Engl J Med. 2003;349:259-266.
10. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615-621.
11. Perfetto EM, Gondek K. Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice. Manag Care Interface. 2002;15:35-42.
12. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med. 2002; 113(suppl 1A):5S-54S.
13. Le TP, Xiong YQ. Gemifloxacin. Drugs Today (Bare). 2001;37:401-410.
14. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 2002;59:334-339.
15. Colgan R, Keating K, Dougouih M. Survey of symptom burden in women with uncomplicated urinary tract infections. Clin Drug Invest. 2004;24: 55-60.
16. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med. 2002;113(suppl 1A):35S-44S.
17. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. Philadelphia, Pa: Churchill Livingstone; 1995:662-690.
18. Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother. 1989;33:92-98.
19. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries [letter] [published correction appears in N Engl J Med. 1998;339:1408]. N Engl J Med. 1998;339:1085-1086.
20. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries [letter] [published correction appears in N Engl J Med. 1998;339:1408]. N Engl J Med. 1998;339:1085-1086.
21. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271:751-754.
22. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322:1-5.
23. Richards DA, Toop LJ, Chambers ST, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J. 2002;115:12-14.
24. Vatopoulos AC, Kalapothaki V, Legakis NJ, Greek Network for the Surveillance of Antimicrobial Resistance. Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Emerg Infect Dis. 1999;5;471-476.
25. Ti TY, Kumarasinghe G, Taylor MB, et al. What is true community-acquired urinary tract infection? comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis. 2003;22:242-245.
26. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-738.
27. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis. 2002;34:1061-1066.
28. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother. 2003;51:69-76.
29. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135:41-50.
30. Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet. 1980;5:405-423.
31. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974;291:1159-1163.
32. Thomas JG. Urinary tract infections. In: Mahon CR, Manuselis G Jr, eds. Textbook of Diagnostic Microbiology. Philadelphia, Pa: WB Saunders Co; 1995:949-969.
33. Kerm MB, Frimodt-Moller N, Espersen F. Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. Antimicrob Agents Chemother. 2003;47:1002-1009.
34. Heffelfinger JD, Dowell SF, Jorgensen JH, et al, Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
35. Raz R, Chazan B, Kennes Y, et al, Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165-1169.
36. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52:729-734.
37. Cizman M, Orazem A, Krizan-Hergouth V, Kolman J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections [letter]. J Antimicrob Chemother. 2001;47:502.
38. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001;18:211-215.
39. Kaufman M. Worries rise over effect of antibiotics in animal feed: humans seen vulnerable to drug-resistant germs. Washington Post. March 17, 2000:A1.
40. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583-1590.
41. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995;273:41-45.
42. McCarty JM, Richard G, Huck W, et al, Ciprofloxacin Urinary Tract Infection Group. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med. 1999;106:292-299.
43. Gomolin IH, Siami PF, Reuning-Scherer J, Haverstock DC, Heyd A, Oral Suspension Study Group. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc. 2001;49:1606-1613.
44. Newsom SW, Murphy P, Matthews J. A comparative study of ciprofloxacin and trimethoprim in the treatment of urinary tract infections in geriatric patients. J Antimicrob Chemother. 1986;18(suppl D):111-115.
45. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999;43(suppl A):67-75.